CRESCITA THERAPEUTICS INC (CTX.CA) Fundamental Analysis & Valuation

TSX:CTX • CA2258471028

Current stock price

0.75 CAD
0 (0%)
Last:

This CTX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CTX.CA Profitability Analysis

1.1 Basic Checks

  • In the past year CTX was profitable.
  • CTX had a positive operating cash flow in the past year.
  • In multiple years CTX reported negative net income over the last 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: CTX reported negative operating cash flow in multiple years.
CTX.CA Yearly Net Income VS EBIT VS OCF VS FCFCTX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M -15M

1.2 Ratios

  • CTX has a Return On Assets of 2.13%. This is in the better half of the industry: CTX outperforms 75.76% of its industry peers.
  • CTX has a better Return On Equity (2.81%) than 75.76% of its industry peers.
Industry RankSector Rank
ROA 2.13%
ROE 2.81%
ROIC N/A
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
CTX.CA Yearly ROA, ROE, ROICCTX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

  • CTX has a Profit Margin of 2.07%. This is in the better half of the industry: CTX outperforms 75.76% of its industry peers.
  • CTX has a Gross Margin of 51.77%. This is in the better half of the industry: CTX outperforms 69.70% of its industry peers.
  • In the last couple of years the Gross Margin of CTX has declined.
Industry RankSector Rank
OM N/A
PM (TTM) 2.07%
GM 51.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
CTX.CA Yearly Profit, Operating, Gross MarginsCTX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CTX.CA Health Analysis

2.1 Basic Checks

  • CTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CTX has been reduced compared to 1 year ago.
  • The number of shares outstanding for CTX has been reduced compared to 5 years ago.
  • The debt/assets ratio for CTX has been reduced compared to a year ago.
CTX.CA Yearly Shares OutstandingCTX.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
CTX.CA Yearly Total Debt VS Total AssetsCTX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of 0.19, we must say that CTX is in the distress zone and has some risk of bankruptcy.
  • CTX's Altman-Z score of 0.19 is fine compared to the rest of the industry. CTX outperforms 60.61% of its industry peers.
  • There is no outstanding debt for CTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.35
Altman-Z 0.19
ROIC/WACCN/A
WACC8.27%
CTX.CA Yearly LT Debt VS Equity VS FCFCTX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 3.12 indicates that CTX has no problem at all paying its short term obligations.
  • CTX has a better Current ratio (3.12) than 78.79% of its industry peers.
  • A Quick Ratio of 2.07 indicates that CTX has no problem at all paying its short term obligations.
  • CTX has a better Quick ratio (2.07) than 78.79% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 2.07
CTX.CA Yearly Current Assets VS Current LiabilitesCTX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. CTX.CA Growth Analysis

3.1 Past

  • CTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 117.32%, which is quite impressive.
  • The Revenue has grown by 26.79% in the past year. This is a very strong growth!
  • CTX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.60% yearly.
EPS 1Y (TTM)117.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%174.35%
Revenue 1Y (TTM)26.79%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%50.06%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTX.CA Yearly Revenue VS EstimatesCTX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

Find the best growth stocksShow best growing peers

3

4. CTX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 37.50 indicates a quite expensive valuation of CTX.
  • Based on the Price/Earnings ratio, CTX is valued a bit cheaper than 72.73% of the companies in the same industry.
  • CTX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.88.
Industry RankSector Rank
PE 37.5
Fwd PE N/A
CTX.CA Price Earnings VS Forward Price EarningsCTX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CTX is valued a bit cheaper than 69.70% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CTX indicates a rather cheap valuation: CTX is cheaper than 81.82% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 9.98
EV/EBITDA 11.23
CTX.CA Per share dataCTX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTX.CA Dividend Analysis

5.1 Amount

  • CTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CTX.CA Fundamentals: All Metrics, Ratios and Statistics

CRESCITA THERAPEUTICS INC

TSX:CTX (3/27/2026, 7:00:00 PM)

0.75

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-25
Earnings (Next)05-12
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners12.94%
Ins Owner ChangeN/A
Market Cap13.96M
Revenue(TTM)22.07M
Net Income(TTM)457.00K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 37.5
Fwd PE N/A
P/S 0.63
P/FCF 9.98
P/OCF 6.87
P/B 0.86
P/tB 0.95
EV/EBITDA 11.23
EPS(TTM)0.02
EY2.67%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.08
FCFY10.02%
OCF(TTM)0.11
OCFY14.57%
SpS1.19
BVpS0.87
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.63
Profitability
Industry RankSector Rank
ROA 2.13%
ROE 2.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2.07%
GM 51.77%
FCFM 6.34%
ROA(3y)-5.89%
ROA(5y)-4.27%
ROE(3y)-7.95%
ROE(5y)-5.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.3%
GM growth 5Y-7.9%
F-Score8
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.35
Debt/EBITDA 0
Cap/Depr 43.64%
Cap/Sales 2.88%
Interest Coverage N/A
Cash Conversion 372.34%
Profit Quality 305.91%
Current Ratio 3.12
Quick Ratio 2.07
Altman-Z 0.19
F-Score8
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)37.08%
Cap/Depr(5y)28.12%
Cap/Sales(3y)2.6%
Cap/Sales(5y)2.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)117.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%174.35%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)26.79%
Revenue growth 3Y5.3%
Revenue growth 5Y-2.6%
Sales Q2Q%50.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y72.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1647.5%
FCF growth 3YN/A
FCF growth 5Y-21.27%
OCF growth 1Y1594.17%
OCF growth 3YN/A
OCF growth 5Y-12.49%

CRESCITA THERAPEUTICS INC / CTX.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CRESCITA THERAPEUTICS INC (CTX.CA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to CTX.CA.


What is the valuation status of CRESCITA THERAPEUTICS INC (CTX.CA) stock?

ChartMill assigns a valuation rating of 3 / 10 to CRESCITA THERAPEUTICS INC (CTX.CA). This can be considered as Overvalued.


How profitable is CRESCITA THERAPEUTICS INC (CTX.CA) stock?

CRESCITA THERAPEUTICS INC (CTX.CA) has a profitability rating of 3 / 10.


What is the financial health of CRESCITA THERAPEUTICS INC (CTX.CA) stock?

The financial health rating of CRESCITA THERAPEUTICS INC (CTX.CA) is 8 / 10.